Company profile: Redx Pharma
1.1 - Company Overview
Company description
- Provider of drug discovery and development advancing clinical-stage assets Zelasudil (ROCK2 inhibitor for idiopathic pulmonary fibrosis and fibrotic diseases), Zamaporvint (Porcupine inhibitor for Wnt-ligand driven cancer), RXC008 (GI-targeted pan-ROCK for fibrostenotic Crohn's), and a Drug Discovery Engine supporting programs in fibrosis and oncology.
Products and services
- Zamaporvint (RXC004): Clinical-stage Porcupine inhibitor offering highly potent, selective, orally active once-daily targeted therapy for Wnt-ligand driven cancer
- Zelasudil (RXC007): Clinical-stage, highly selective, orally available ROCK2 inhibitor being developed for idiopathic pulmonary fibrosis and fibrotic diseases
- Drug Discovery Engine: Platform-based capability advancing a pipeline of research programs and collaborations in fibrotic diseases and oncology, focused on improving characteristics of existing drug classes to create best-in-class new drugs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Redx Pharma
Pernix Therapeutics
HQ: United States
Website
- Description: Provider of branded and generic pharmaceutical products for the pediatric market, specializing in the sales, marketing, and development of products designed to improve children's health and well-being, including offerings in allergy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pernix Therapeutics company profile →
DJS Antibodies
HQ: United Kingdom
Website
- Description: Provider of antibody therapeutics and discovery technology targeting GPCRs to treat chronic inflammatory and fibrotic diseases. Offers HEPTAD, a proprietary platform to discover functional, first-in-class antibodies for complex protein targets; DJS 001, a first-in-class program for myeloid cell driven inflammatory disease; and DJS 002, a monoclonal antibody for fibrotic diseases without off-target side effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DJS Antibodies company profile →
Veru
HQ: United States
Website
- Description: Provider of novel medicines and healthcare products, including enobosarm to prevent muscle loss in patients using GLP-1 drugs and to treat metastatic breast cancer; sabizabulin for hospitalized patients with viral-induced ARDS; and the FDA-approved FC2 Female Condom for prevention of pregnancy and sexually transmitted infections, available by prescription.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Veru company profile →
Covis Pharma
HQ: Switzerland
Website
- Description: Provider of branded and generic pharmaceutical products and injectables for life-threatening and serious medical conditions across cardiovascular, CNS, oncology, and acute care. Portfolio includes Alvesco for asthma, Omnaris and Zetonna for nasal allergies, Feraheme for iron deficiency anemia, and Duaklir and Tudorza Pressair for COPD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Covis Pharma company profile →
Innate Pharma
HQ: France
Website
- Description: Provider of first-in-class immunotherapy drug candidates for cancer and inflammatory diseases, specializing in novel monoclonal antibodies and NK cell engagers targeting innate immunity pathways. Pipeline includes ANKET; Lacutamab for cutaneous and peripheral T cell lymphomas; Monalizumab (anti-NKG2A) and CD39 with AstraZeneca for NSCLC and other solid tumors; CD123 and B7-H3 multi-specific ANKETs with Sanofi.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Innate Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Redx Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Redx Pharma
2.2 - Growth funds investing in similar companies to Redx Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Redx Pharma
4.2 - Public trading comparable groups for Redx Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →